Erythrasma: A report of nine men successfully managed with mupirocin 2&amp;#37; ointment monotherapy

Greywal, Tanya; Cohen, Philip R.

doi:10.5070/d3235034927

Cited by 12 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study a case of erythrasma has been reported during following COVID-19 inpatient, the occurrence of erythrasma concurrent or before COVID-19 infection has not been reported before according to our knowledge, its occurrence in this patient might be due to high fever and subsequent over sweating, as it is commonly affects the groin, axillae, intergluteal folds, sub-mammary region, and interdigital spaces of the toes. Heat, humidity, obesity, diabetes mellitus, hyperhidrosis, and poor hygiene are predisposing factors [22]. In other hand there are a plethora of semi-specific determined known cutaneous manifestations have been reported in a floods of publications as six main clinical patterns of COVID-19-associated cutaneous manifestations urticarialrash, confluent erythematous/maculopapular/morbilliform rash, papulovesicular exanthem, chilblain like acral pattern, and livedo reticularis/racemosa-like pattern (24,25,26).…”

Section: Discussionmentioning

confidence: 99%

Skin Manifestations in Confirmed COVID 19 Patients; A Short Prospective Multicenter Case Series Cohort Study

Almasy¹

2022

J Clin Stud Rev Rep

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Skin Manifestations in Confirmed COVID 19 Patients; A Short Prospective Multicenter Case Series Cohort Study

Almasy¹

2022

J Clin Stud Rev Rep

View full text Add to dashboard Cite

“…Coexistence with herpes simplex infection or candidiasis has been observed [2]. For its part, erythrasma is a bacterial skin infection that occurs mainly in intertrigos of obese and diabetic patients [8]. Being the main treatment in lichen scleroatrophicus with high potency topical corticosteroids, treatment failures may be implicated in case of superimposed infections [2].…”

Section: Discussionmentioning

confidence: 99%

"Intertriginous Erythrasma Concomitant to Vulvar Lichen Sclerosus and Atrophicus"

2022

BJSTR

View full text Add to dashboard Cite

Erythrasma and lichen sclerosus are usually found as separate entities, however it is rare for the two diseases to coexist in a patient in the same affected area. Next, we present the case of an adult, Afro-Colombian, and obese patient with a primary diagnosis of lichen sclerosus on the vulva, which is refractory to treatment with potent topical glucocorticoids secondary to the association with erythrasma in the same area.Summary: Erythrasma and lichen sclerosus are usually found as separate entities, however it is rare for the two diseases to coexist in a patient in the same affected area. Next, we present the case of an adult, Afro-Colombian, and obese patient with a primary diagnosis of lichen sclerosus on the vulva, which is refractory to treatment with potent topical glucocorticoids secondary to the association with erythrasma in the same area.

show abstract

“…Decolonization can decrease the risk of MRSA infections in patients and reduce the transmission to other patients [33]. Furthermore, clinical studies revealed that monotherapy with MUP 2% ointment was effective for the treatment of erythrasma [34] and Zoon's balanitis [35]. Additionally, MUP-loaded nanoliposomes were used for the treatment of multidrug-resistant Neisseria gonorrhoeae [27].…”

Section: Clinical Application and Mechanism Of Actionmentioning

confidence: 99%

Recent Advances in Mupirocin Delivery Strategies for the Treatment of Bacterial Skin and Soft Tissue Infection

Gangwar

Kumar²,

Singh

et al. 2021

Future Pharmacology

View full text Add to dashboard Cite

Skin and soft tissue infections (SSTIs) have increased problematically in hospital and ambulatory settings due to the poor immunity of hosts and multidrug-resistant pathogens. Mupirocin (MUP), a global topical antibiotic, is used for the treatment of SSTIs caused by various pathogens due to its unique mechanism of action. However, the therapeutic efficiency of MUP is hampered due to the protein binding and drug resistance caused by frequent use. A combined report covering the various aspects of MUP, such as the synthesis of the novel formulation, loading of the drug, and application against various skin infections, is missing. This comprehensive review focuses on various novel drug delivery strategies such as composite biomaterials/scaffold, hydrogel dressings, liposomes, liposomal hydrogel, microparticles/microspheres, microsponges, nanocapsules, nanofibers, silicone-based adhesive patches, and topical sprays. The therapeutic effect of the MUP can be synergized by combining with other agents and using novel strategies. The objective is to enhance patient compliance, decrease the resistance, magnify the delivery of MUP, and overcome the limitations of conventional formulations. Moreover, the carriers/dressing materials are biocompatible, biodegradable, stimulate wound healing, protect the wound from external environmental contamination, adsorb the wound exudates, and are permeable to oxygen and moisture. This review will help researchers to explore further the treatment of various bacterial skin infections by using MUP-loaded novel formulations with better efficacy, utilizing the novel nanostructures or combinatorial methods.

show abstract

Erythrasma: A report of nine men successfully managed with mupirocin 2% ointment monotherapy

Cited by 12 publications

References 11 publications

Skin Manifestations in Confirmed COVID 19 Patients; A Short Prospective Multicenter Case Series Cohort Study

Skin Manifestations in Confirmed COVID 19 Patients; A Short Prospective Multicenter Case Series Cohort Study

"Intertriginous Erythrasma Concomitant to Vulvar Lichen Sclerosus and Atrophicus"

Recent Advances in Mupirocin Delivery Strategies for the Treatment of Bacterial Skin and Soft Tissue Infection

Contact Info

Product

Resources

About